Platform presentations of selected Hematopathology abstracts.
H034 - Identification of Neoplastic Clonal T-cell Sequences in Unrelated Healthy Individuals: Limitations of High Throughput TRG Sequencing for Minimal Residual Disease (MRD) Analysis
Siddhartha Sen, MD, PhD, Duke University Medical Center, Durham, NC, USA
H039 - Measurable Residual Disease Monitoring for Patients with Acute Myeloid Leukemia Following Hematopoietic Cell Transplantation Using Error Corrected Hybrid Capture Next Generation Sequencing
Vidya Balagopal, PhD, University of Chicago, Chicago, IL, USA
H021 - IGH locus assessment using hybrid-capture, a proof-of-concept study
Etienne Mahe, MD, MSc, FRCPC, FCAP, University of Calgary, Calgary, Alberta, Canada
H027 - Convergence on Genomic Abrogation of the DNA Damage Response Pathway in CLL is Observed in Patients with Loss of18p
Waihay Wong, Brigham and Women's Hospital and Harvard Medical School
H020 - IDH1 p.S280F mutation is potentially a novel mechanism of resistance to Ivosidenib therapy in an IDH1 positive acute myeloid leukemia
Zoltan Oltvai, MD, University of Pittsburgh, Pittsburgh, PA, USA
Objectives:
- Analyze platform presentations of abstracts highlighted by the Hematopathology Subdivision leadership as particularly significant.
- Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.
Duration: 1.25 hr
Recording Date: November 7, 2019
CME/CMLE credit: 1.25 hr
Last day to purchase course and CE claim credit: December 24, 2022
